Enzymatic beacons, or E-beacons, are 1:1 bioconjugates of the nanoluciferase enzyme linked covalently at its C-terminus to hairpin forming DNA oligonucleotides equipped with a dark quencher. We prepared E-beacons biocatalytically using the promiscuous "hedgehog" protein-cholesterol ligase, HhC. Instead of cholesterol, HhC attached nanoluciferase site-specifically to mono-sterylated hairpin DNA, prepared in high yield by solid phase synthesis. We tested three potential E-beacon dark quenchers: Iowa Black, Onyx-A, and dabcyl. Prototype E-beacon carrying each of those quenchers provided sequence-specific nucleic acid sensing through turn-on bioluminescence. For practical application, we prepared dabcyl-quenched E-beacons for potential use in detecting the COVID-19 virus, SARS-CoV-2. Targeting the E484 codon of the SARS-CoV-2 Spike protein, E-beacons (80 × 10 -12 M) reported wild-type SARS-CoV-2 nucleic acid at ≥1 × 10 -9 M with increased bioluminescence of 8-fold. E-beacon prepared for the E484K variant of SARS-CoV-2 functioned with similar sensitivity. These E-beacons could discriminate their complementary target from nucleic acid encoding the E484Q mutation of the SARS-CoV-2 Kappa variant. Along with specificity, detection sensitivity with E-beacons is two to three orders of magnitude better than synthetic molecular beacons, rivaling the most sensitive nucleic acid detection agents reported to date.
Enzymatic beacons, or E-beacons, are 1:1 bioconjugates of the nanoluciferase enzyme linked covalently at its C-terminus to hairpin forming DNA oligonucleotides equipped with a dark quencher. We prepared E-beacons biocatalytically using the promiscuous "hedgehog" protein-cholesterol ligase, HhC. Instead of cholesterol, HhC attached nanoluciferase site-specifically to mono-sterylated hairpin DNA, prepared in high yield by solid phase synthesis. We tested three potential E-beacon dark quenchers: Iowa Black, Onyx-A, and dabcyl. Prototype E-beacon carrying each of those quenchers provided sequence-specific nucleic acid sensing through turn-on bioluminescence. For practical application, we prepared dabcyl-quenched E-beacons for potential use in detecting the COVID-19 virus, SARS-CoV-2. Targeting the E484 codon of the SARS-CoV-2 Spike protein, E-beacons (80 × 10 -12 M) reported wild-type SARS-CoV-2 nucleic acid at ≥1 × 10 -9 M with increased bioluminescence of 8-fold. E-beacon prepared for the E484K variant of SARS-CoV-2 functioned with similar sensitivity. These E-beacons could discriminate their complementary target from nucleic acid encoding the E484Q mutation of the SARS-CoV-2 Kappa variant. Along with specificity, detection sensitivity with E-beacons is two to three orders of magnitude better than synthetic molecular beacons, rivaling the most sensitive nucleic acid detection agents reported to date.
Reagents for the specific detection of dilute nucleic acid are fundamental to molecular and cellular genetics and various clinical diagnostics, including tests for viral pathogens like SARS-CoV-2.[1-4] Molecular beacons, the fluorogenic hairpin-forming oligonucleotide-based sensors, have provided a standard detection tool.[5, 6] Modified with fluorophore and quencher at opposite ends, the oligonucleotide fluorescence is suppressed in the hairpin, or off state. Molecular beacons switch on by hybridizing to complementary nucleic acid, which separates the fluorophore and quencher, increasing radiative emission. Improvements to molecular beacon technology have been driven mainly through chemical synthesis with the introduction of more efficient quenchers and new fluorophore/quencher pairs.[7]Here we describe an alternative strategy where enzymatic catalysis is employed in the preparation of the sensor and for the sensor output. In enzymatic beacons or E-beacons the fluorophore of a molecular beacon is replaced by the compact, ATP-independent bioluminescent enzyme, nanoluciferase (Nluc).[8-11] This substitution provides an internal, amplifiable light source. Nluc with the engineered substrate furimazine produces light that is sufficiently bright for measurement with portable luminometer.[12] Moreover, we expected that nucleic acid detection assays would consume less reagent while improving detection sensitivity relative to synthetic molecular beacons.To connect Nluc to a hairpin-forming oligonucleotide as a potential E-beacon, we applied the protein-nucleic acid bioconjugation activity of hedgehog proteins (Figure 1A).[13] Hedgehog proteins harbor a promiscuous autoprocessing domain, HhC, that catalyzes two linked activities: self-cleavage from an adjacent N-terminal protein, and site-specific sterol ligation to that departing N-terminal protein. These reactions occur simultaneously without cofactor requirements. We have found that the Drosophila melanogaster HhC has broad substrate tolerance, maintaining robust bioconjugation activity toward heterologous substrate proteins and catalyzing ligation with sterols of varying structure and chemical appendages, including oligonucleotides.[13, 14] For E-beacons, we fused this promiscuous HhC to the C-terminus of the Nluc enzyme (Supporting Methods).
FIGURE 1.
Concept and biocatalytic preparation of prototype E-beacon (A) Scheme showing HhC catalyzed bioconjugation of Nluc (grey) to a hairpin-forming mono-sterylated oligonucleotide (steramer) equipped with a 3’ dark quencher (Q). Conjugation involves formation of an internal thioester (step 1), followed by steramer binding and acyl transfer to the sterol hydroxyl group (step 2). (B) General mechanism for turn-on nucleic acid detection by E-beacon, whereby hybridization of hairpin oligonucleotide with complementary nucleic acid displaces the quencher (Q) from the Nluc enzyme, enhancing bioluminescence signal. (C) E-beacon preparation monitored by SDS-PAGE. A fusion of Nluc with HhC is purified first by Ni-NTA chromatography, followed by size exclusion chromatography (SEC), then reacted with steramer (conjugation). E-beacon is isolated by agarose gel extraction. Nucleic acid was visualized by UV with GelRed staining.
To serve as a substrate for ligation to Nluc, the hairpin oligonucleotide component required mono-sterylation. Our initial tests used an ssDNA oligo with the sequence: (5’-amino)-CGCTCCCAAAAAAAAAAACCGAGCG-(3’-IBQ). The underlined regions self-anneal to form the hairpin stem; the italicized 15 nucleotides in the middle represent the probe region for target nucleic acid hybridization. The same sequence was used by Kramer, Tyagi et al for their early biophysical studies on molecular beacons.[15] We used the IowaBlack (IBQ) dark quencher at the 3’-end to suppress Nluc bioluminescence in the hairpin (off) state (Figure 1B). Mono-sterylation was achieved by coupling the oligo’s 5’-amino group to the carboxyl group of 23,24-bisnor 5-cholenic acid (Supporting Methods).[a]We prepared a prototype E-beacon, Eb.1, by combining the Nluc-HhC precursor protein with mono-sterylated hairpin-forming oligonucleotide. His-tagged Nluc-HhC precursor was expressed in E. coli and purified in soluble form by Ni-NTA resin and size exclusion chromatography (Figure 1C, lanes 1–2). Site-specific bioconjugation of Nluc to the modified hairpin was carried out in vitro.[13] In a typical reaction, we combined Nluc-HhC precursor at 2 μM (final) with 25–50-fold excess of hairpin in HhC buffer, incubated on the benchtop overnight, and assessed reaction progress by SDS-PAGE (Figure 1C, see conjugation). Agarose gel extraction provided a convenient means of purifying the conjugate, Eb.1 (Figure 1C, last two lanes).We observed encouraging nucleic acid sensing with Eb.1. As an initial test, bioluminescence readings from samples with Eb.1 plus oligonucleotide complementary to the hairpin probe region (signal; GGTTTTTTTTTTTGG) were collected and compared with bioluminescence readings from Eb.1 mixed with non-complementary oligonucleotide (noise; CTGGTCTTCGGGCTA). Eb.1 was present at 2 × 10−9 M, oligonucleotide was added to 25 × 10−9 M. Samples were incubated in hybridization buffer (KCl 100 mM, MgCl2 1 mM, in 10 mM Tris buffer, pH 8) at 25 °C for 30 min. The Nluc substrate furimazine was then added according to manufacturer instructions (Promega).[8] Representative data from a 96-well experiment are summarized in Figure 2A. The average ratio of Eb.1 signal (with target) to noise (with random oligo) was 2.5–3-fold. The increased bioluminescence from Eb.1 in samples with complementary oligo accords with the unquenching mechanism[5, 6]: target/probe hybridization displaces the 3’quencher from the light source, here Nluc, permitting brighter signal.[b]
FIGURE 2.
E-beacon proof of concept and sequence specific nucleic acid detection*
(A) Bioluminescence from Eb.1 increases in the presence of complementary oligonucleotide (green, n=48) compared to E-beacon samples mixed with noncomplementary oligonucleotide (red, n=48). (B) Results of “blinded test” of Eb.1 specificity indicate that Eb.1 distinguishes complementary oligonucleotide (green) from oligonucleotides containing 1–3 base mismatches. See Table 1 for sequence information. (C) Comparison of E-beacons with different quenchers: IowaBlack, dabcyl, and ONYX-A. Bioluminescence was measured after 10-minute incubation with complementary oligonucleotide (green, n=48) or noncomplementary oligonucleotide (red, n=48). *In A, B, and C, the E. beacon was present at 2 × 10−9 M final; oligonucleotide at 25 × 10−9 M; temperature, 25 °C; substrate, furimazine.
Next, we more stringently evaluated the specificity of Eb.1 as a nucleic acid reporter by measuring bioluminescence output when combined with oligonucleotides carrying only one to three mismatches with the hairpin probe region. Oligonucleotide sequences are listed in Table 1. As above, each oligonucleotide was added to 25 × 10−9 M in hybridization buffer containing Eb.1 at 2 × 10−9 M. The experiments were carried out “blinded”: one member of the lab distributed complementary and mismatched oligonucleotides into sample wells of a 96-well plate in a semi-random pattern; another lab member without knowledge of the plate layout added Eb.1 and carried out the bioluminescence measurement and data analysis. The results of a representative specificity test are summarized in Figure 2B. The largest difference in Eb.1 bioluminescence is apparent between the perfectly complementary target and the fully mismatched template (signal/noise, 3-fold). No increase in bioluminescence was apparent in wells containing oligo with mismatches of two and three base pairs (G2 and G3). Oligo with one mismatch (G1) in the center of the probe sequence produced 10% unquenching of the E-beacon. Unquenching of 15–20% of Eb.1 was observed when mixed with oligo G2F, carrying (T-to-G) mismatches to the probe region at both the 3’ and the 5’ flanks. Nonetheless, samples of Eb.1 with G1 and G2F, compared to samples with Eb.1 plus the complementary oligo were easily distinguished. The fidelity of Eb.1 observed here suggested that this prototype’s specificity, like a molecular beacon,[5, 6] was sufficiently strong for detecting subtle sequence variations.
TABLE 1.
Sequences of hairpin oligonucleotides for E-beacons and ssDNA oligonucleotides used for evaluating E-beacon function.
Name
Sequence
Eb.1–3
[S]-CGCTC CCAAAAAAAAAAACC GAGCG-[Q]
EB.1 Target:
GGTTTTTTTTTTTGG
Random:
CTGGTCTTCGGGCTA
G1:
GGTTTTGTTTTTTGG
G2:
GGTTTTGGTTTTTGG
G3:
GGTTTTGGGTTTTGG
G2F:
GGGTTTTTTTTTGGG
C3:
GGTTTTCCCTTTTGG
Eb.19(WT)
[S]-CGCTC TGGTGTTGAAGGTTT GAGCG-[Q]
E484 Target
(3’) ACCACAACTTCCAAA (5’)
Eb.19(E484K)
[S]-CGCTC TGGTGTTAAAGGTTT GAGCG-[Q]
E484K Target
(3’) ACCACAATTTCCAAA (5’)
E484Q Target
(3’) ACCACAAGTTCCAAA (5’)
Red =mismatch; Bold = codon 484 of SARS-CoV2–2 spike protein; [S] sterol; [Q] quencher
While encouraged by the results above, we viewed the signal/noise range of ~3 as narrow (Z’ factor[16], 0.46) and this led us to explore other quencher groups. The peak bioluminescence from the Nluc/ furimazine reaction occurs at 460 nm. The maximum absorbance for the Iowa Black quencher is 531 nm. As alternative dark quenchers, we evaluated dabcyl and ONYX-A (Sigma). The dabcyl max absorbance peak is 453 nm and the ONYX_A absorbance peak is 515 nm. For meaningful comparison with Eb.1, we prepared new E-beacons from mono-sterylated oligonucleotide carrying the same sequence as Eb.1 and we applied the same biocatalytic approach for site-specific attachment to the C-terminus of Nluc. The dabcyl containing E-beacon, Eb.2, and the ONYX E-beacon, Eb.3, were likewise isolated by agarose gel extraction.Changing the E-beacon quencher improved signal/noise and assay quality, in the order ONYX-A> dabcyl> IBQ. Figure 2C compares Eb.1 Eb.2 and Eb.3 readings with E-beacons at 2 × 10−9 M and complementary or random oligo at 25 × 10−9 M. Eb.3 with the ONYX quencher showed the highest single/noise of 8.7-fold and Z’ of 0.79. Using the dabcyl quencher in Eb.2, the signal/noise was 6, better than IBQ, however the scatter in readings dropped the Z’ to 0.47. Because the oligonucleotide sequences in EB.1–.3 were the same, the changes in signal/noise are difficult to explain in terms of intra-oligo interactions, solution properties of the E-beacons, or Nluc activity; they seem more likely the result of specific photochemical characteristics (e.g. quenching efficiency). Structural information on SIGMA’s ONYX quencher which might have helped interpret these results is not yet available.Lastly and with a view toward application, we designed and tested prototype E-beacons for SARS-CoV-2 detection. Reliable assays for rapid identification of patients infected with SARS-CoV-2, particularly those shedding viable virus, remain crucial to pandemic management. In considering how to configure the E-beacon for high-volume testing, we settled on using the dabcyl quencher because it is widely available. We also shifted our oligonucleotide sterylation protocol from microscale EDC-based coupling to a more robust solid phase method with a DNA synthesizer. The solid phase synthesis routinely provided >90% oligonucleotide sterylation efficiency and the modified oligos could be used without additional purification for Nluc conjugation. We found that E-beacon prepared this way displayed favorable S/N of 8–9 fold and Z’ factor >0.8 in test assays (see Supporting Figure 1 and Supporting Methods).We selected the spike protein of SARS-CoV-2 as target for this new set of E-beacons. We focused on the region encompassing glutamate 484 of spike as changes at this codon can distinguish wild-type SARS-CoV-2 from emerging variants. The E-beacon intended for wild-type, Eb.19(WT), was prepared by HhC catalyzed ligation of Nluc to the sterylated hairpin: (sterol)-5’-CGCTCTGGTGTTGAAGGTTTGAGCG-3’-(dabcyl). A second E-beacon was prepared for detecting the E484K mutation, which is present in certain α and all β and γ strains of SARS-CoV-2. This Eb.19(E484K) carried the hairpin oligo: (sterol)-5’-CGCTCTGGTGTTAAAGGTTTGAGCG-3’-(dabcyl). The bold text represents the spike 484 codon.We explored potential assay conditions for the SARS E-beacons in two stages. First, we sought to determine the minimum working concentration of E-beacon. In our experiments, the concentration of target oligonucleotide was held constant and in excess at 1 × 10−7 M, while the E-beacon was titrated from 1 × 10−8 M to 1 × 10−16 M. Bioluminescence readings from substrate furimazine were recorded as before. A positive result was defined arbitrarily as having a signal/noise of >5, anything less was deemed ambiguous. With the S/N threshold at 5, the lowest possible operating concentration of Eb.19 (WT) was 3 × 10−13 M (Supporting Figure 2)[c].In stage two, we held the E-beacon concentration constant and titrated the test oligos to find the nucleic acid detection threshold. We chose to use 8 × 10−11 M for the E-beacon. Although higher than the minimum Eb.19 (WT) concentration defined above, we selected 80 pM to avoid pitfalls associated with assaying biomolecules in the extremely dilute regime, such as slow association kinetics and idiosyncratic adsorption effects, i.e., “death by dilution”. The assay parameter we sought was the EC50 or the concentration of target oligo that could produce 50% unquenching of Eb.19 (WT). We also explored the effect of E-beacon/oligo incubation time on sensor output. In Figure 3A, we show bioluminescence readings of samples with Eb.19 (WT) plotted as a function of increasing target oligo concentration after 10 min incubation and 3 hr incubation. Hyperbolic binding isotherms could be fit to the data to derive EC50 values. For Eb.19 (WT) the EC50 was 1.64 × 10−9 M for the 10 min incubation; for 3 hr incubation of Eb.19(WT) and oligo, the assay was 15-fold more sensitive, EC50 of 0.11 × 10−9 M. Similar behavior was observed with Eb.19 (E484K) (Supporting Figure 3). The improved sensitivity (lower EC50) with a 3 hr incubation of Eb19 (WT) and target oligo indicates that “slow” probe/target hybridization should be considered when attempting to detect very dilute nucleic acid.
FIGURE 3.
E-beacons for SARS-CoV-2 (A) Bioluminescence readings of samples with Eb.19 (WT) after 10 min or 3 hr incubation with increasing concentration of complementary oligonucleotide. The curves show hyperbolic binding isotherms with calculated half maximum emission (EC50) at 2.54 × 10−9 M of oligonucleotide using the 10 min incubation, and 0.11 × 10−9 M for the 3 incubation. (B) Single base-pair mismatch discrimination by E-beacon, Eb.19 (WT). Bioluminescence from Eb.19(WT), at 80 × 10−12 M, is plotted as a function of increasing oligonucleotide concentration. E484 is the complementary target, E484K is single base pair mismatch, “random” is non-complementary (see Table 1). (C) Bioluminescence spectrum showing the selective detection of E484K oligonucleotide by E-beacon, Eb.19 (E484K). Oligonucleotides E484 and E484Q represent single base pair variants of wild type SARS-CoV-2 and Kappa SARS-CoV-2, respectively.
To assess specificity, we compared signal from samples of Eb.19 (WT) mixed with the target oligo to signal from samples of Eb.19 (WT) mixed with the random oligo and the E484K variant oligo (single base-pair mismatch). As with the Eb.1 prototype, the random oligo did not unquench Eb.19 (WT) over the entire concentration range tested (10−12 to 10−7 M) (Figure 3B, lowest trace). Unquenching of Eb.19 (WT) did become apparent in samples containing the E484K oligo when added >10−8 M, although bioluminescence remained below samples with the fully complementary target oligo (Figure 3B, compare squares and circles). In Figure 3C, we present selectivity data for Eb.19 (E484K) in the form of comparative bioluminescence spectra. Here Eb.19 (E484K) was mixed with either E484K target oligo (Figure 3C, top trace), with random oligonucleotide, E484 (WT) or an oligo corresponding to E484Q of the SARS-CoV-2 Kappa variant. Once again, although some unquenching is apparent with base variants, signal of Eb.19 (E484K) was greatest with the fully complementary target, E484K (6–8 fold). Together, the results in Figure 3 A–C are promising and show that with 80 pM E-beacon, nucleic acid detection is sensitive and base pair specific.In summary, we report the preparation and analysis of E-beacons, enzymatic bioluminescent counterparts to synthetic fluorogenic molecular beacons. The general concept was introduced by Deo and her associates who assembled a (Renilla) luciferase-hairpin oligonucleotide-(3’-dabcyl) conjugate for microRNA detection,[10] and subsequently created a (Gaussia) luciferase-hairpin oligonucleotide-(3’-dabcyl) conjugate for HIV detection[9] and see also Ref[17]. The Deo sensors were prepared by spontaneous coupling of hairpin-forming oligos onto reactive residues of those luciferase enzymes. Spontaneous coupling is relatively inexpensive, but the technique produces heterogeneity in enzyme: oligonucleotide stoichiometry (1:1, 1:2, 1:3 etc) and the site(s) of attachment can vary between batches. We prepare E-beacons by site-specific C-terminal coupling of nanoluciferase using HhC as the bioconjugation catalyst.[13] This approach yields 1:1 enzyme: oligonucleotide stoichiometry. HhC catalyzed bioconjugation requires mono-sterylated oligonucleotides (steramers). Although steramers are not yet available commercially, we show here that they can be obtained in >90% yield from commercial reagents on a DNA synthesizer. E-beacons prepared by this approach for SARS-Cov-2 showed sensitive and sequence specific nucleic acid detection. Synthetic molecular beacons are used at ~ 1 × 10−7 M; the Deo sensors were used at 2 × 10−9 M; E-beacons with the ultrabright Nluc/furimazine reaction are effective in the mid to low pM range. Because such a small quantity of E-beacon is needed for each assay, a micro-scale E-beacon preparation yields sufficient reagent for testing thousands of samples.
Authors: Daniel A Ciulla; Andrew G Wagner; Xinyue Liu; Courtney L Cooper; Michael T Jorgensen; Chunyu Wang; Puja Goyal; Nilesh K Banavali; John L Pezzullo; José-Luis Giner; Brian P Callahan Journal: Chem Commun (Camb) Date: 2019-02-05 Impact factor: 6.222
Authors: Xiaoyu Zhang; Zihan Xu; Dina S Moumin; Daniel A Ciulla; Timothy S Owen; Rebecca A Mancusi; José-Luis Giner; Chunyu Wang; Brian P Callahan Journal: Bioconjug Chem Date: 2019-10-10 Impact factor: 4.774
Authors: Susanna K Elledge; Xin X Zhou; James R Byrnes; Alexander J Martinko; Irene Lui; Katarina Pance; Shion A Lim; Jeff E Glasgow; Anum A Glasgow; Keirstinne Turcios; Nikita S Iyer; Leonel Torres; Michael J Peluso; Timothy J Henrich; Taia T Wang; Cristina M Tato; Kevin K Leung; Bryan Greenhouse; James A Wells Journal: Nat Biotechnol Date: 2021-03-25 Impact factor: 54.908
Authors: Wouter Engelen; Kayleigh M van de Wiel; Lenny H H Meijer; Bedabrata Saha; Maarten Merkx Journal: Chem Commun (Camb) Date: 2017-03-02 Impact factor: 6.222
Authors: Melissa M Arons; Kelly M Hatfield; Sujan C Reddy; Anne Kimball; Allison James; Jesica R Jacobs; Joanne Taylor; Kevin Spicer; Ana C Bardossy; Lisa P Oakley; Sukarma Tanwar; Jonathan W Dyal; Josh Harney; Zeshan Chisty; Jeneita M Bell; Mark Methner; Prabasaj Paul; Christina M Carlson; Heather P McLaughlin; Natalie Thornburg; Suxiang Tong; Azaibi Tamin; Ying Tao; Anna Uehara; Jennifer Harcourt; Shauna Clark; Claire Brostrom-Smith; Libby C Page; Meagan Kay; James Lewis; Patty Montgomery; Nimalie D Stone; Thomas A Clark; Margaret A Honein; Jeffrey S Duchin; John A Jernigan Journal: N Engl J Med Date: 2020-04-24 Impact factor: 91.245
Authors: Daniel B Larremore; Bryan Wilder; Evan Lester; Soraya Shehata; James M Burke; James A Hay; Milind Tambe; Michael J Mina; Roy Parker Journal: Sci Adv Date: 2021-01-01 Impact factor: 14.136